Bovine collagen was approved by the Food and Drug Administration in 1982 and since that time has remained a primary filler of choice for soft-tissue augmentation of dermal defects. During the past decade, however, perhaps mirroring the growth and overwhelming acceptance of botulinum toxin for wrinkle reduction, there has been an increase in demand and availability of new injectable filler products. A partial list includes the ever-expanding class of hyaluronans (hyaluronic acids), calcium hydroxylapatite, polymethylmethacrylate, poly-L-lactic acid, and silicone oil. There are many more on the immediate horizon that are under investigation both abroad and in the United States. Nevertheless, the collagen family of agents, regardless of their source of derivation, remain a reliable and useful alternative. They have an unparalleled record of safety and efficacy; they have different formulations, which makes them amenable to many indications and user friendly for the physician. And, for patient, the admixture of local anesthesia reduces the discomfort of the injection procedure.

Semin Cutan Med Surg 25:151-157 © 2006 Elsevier Inc. All rights reserved.

During the past decade, however, perhaps mirroring the growth and overwhelming acceptance of botulinum toxin for wrinkle reduction, there has been an increase in demand and availability of new injectable filler products.